Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop
the growth of malignant melanoma by blocking blood flow to the tumor. Drugs used in
chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving sorafenib together with
bevacizumab and oxaliplatin may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side-effects and best dose of sorafenib when
given together with bevacizumab and oxaliplatin and to see how well it works in treating
patients with metastatic malignant melanoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
San Diego Pacific Oncology & Hematology Associates